Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAGE Niagen Bioscience

Post-Mkt 03-04 18:56:18 EST

4.94

+0.07

+1.44%

盘后5.94

+1.00+20.24%

18:56 EST

High5.04	Low4.82	Vol7.21M
Open4.94	D1 Closing4.87	Amplitude4.62%
Mkt Cap394.80M	Tradable Cap253.99M	Total Shares79.92M
T/O42.61M	T/O Rate14.02%	Tradable Shares51.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":4.94,"timestamp":1772658000000,"preClose":4.87,"halted":0,"volume":7207652,"hourTrading":{"tag":"盘后","latestPrice":5.94,"preClose":4.94,"latestTime":"18:56 EST","volume":3109337,"amount":20119111.197339,"timestamp":1772668575607,"change":1,"changeRate":0.202429,"amplitude":0.477733},"delay":0,"changeRate":0.01437371663244359,"floatShares":51414700,"shares":79919957,"eps":0.234893,"marketStatus":"Post-Mkt","change":0.07,"latestTime":"03-04 18:56:18 EST","open":4.94,"high":5.04,"low":4.815,"amount":42614069.765019596,"amplitude":0.046201,"askPrice":5.95,"askSize":21,"bidPrice":5.93,"bidSize":500,"shortable":3,"etf":0,"ttmEps":0.234893,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772672400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":4.87,"preHourTrading":{"tag":"盘前","latestPrice":4.9696,"preClose":4.87,"latestTime":"09:29 EST","volume":3447,"amount":17063.011935,"timestamp":1772634590630,"change":0.0996,"changeRate":0.020452,"amplitude":0.020534},"postHourTrading":{"tag":"盘后","latestPrice":5.94,"preClose":4.94,"latestTime":"18:56 EST","volume":3109337,"amount":20119111.197339,"timestamp":1772668575607,"change":1,"changeRate":0.202429,"amplitude":0.477733},"volumeRatio":6.070856,"impliedVol":2.0727,"impliedVolPercentile":0.9461},"requestUrl":"/m/hq/s/NAGE/wiki","defaultTab":"wiki","newsList":[{"id":"2617667425","title":"Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617667425","media":"Benzinga","labels":["dataReport","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2617667425?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658193,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 127.27 percent. This is a 44.44 percent decrease over earnings of $0.09 per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51050229/niagen-bioscience-q4-eps-0-05-beats-0-02-estimate-sales-33-839m-beat-31-705m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2617629245","title":"Niagen Bioscience Inc. Publishes Investor Presentation on NAD+ and Healthy Aging Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2617629245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617629245?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:29","pubTimestamp":1772663384,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. released an investor presentation outlining its NAD+ product portfolio, including the Tru Niagen supplement and the Niagen Plus lineup for IV and injectable formats. The company reported FY 2025 revenue of $129.4 million, net income of $17.4 million, and cash of $64.8 million with no debt. The presentation also highlighted Niagen IV and injectables initiatives, including an NAD+ test kit and a targeted at-home injectable product launch in the first half of 2026, and noted early adoption metrics since the August 2024 launch. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news bri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL1bj7jx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"gpt_icon":0},{"id":"2617649875","title":"Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2617649875","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617649875?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:45","pubTimestamp":1772660741,"startTime":"0","endTime":"0","summary":"Consensus $152.9M. Sees FY26 gross margin with “slight improvement year-over-year, driven by improvements in inventory cost and product mix.” Publi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-sees-fy26-revenue-up-10-15-implying-142-3m-148-8m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-sees-fy26-revenue-up-10-15-implying-142-3m-148-8m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE"],"gpt_icon":0},{"id":"2617646085","title":"Niagen Bioscience up 39% at $6.88 after Q4 results and guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2617646085","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617646085?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:45","pubTimestamp":1772660721,"startTime":"0","endTime":"0","summary":"16:41 EST Niagen Bioscience (NAGE) up 39% at $6.88 after Q4 results and guidance Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-up-39-at-6-88-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-up-39-at-6-88-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","NAGE","BK4121"],"gpt_icon":0},{"id":"2617569526","title":"Niagen Bioscience Q4 net sales rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569526","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569526?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:12","pubTimestamp":1772658744,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Q4 net sales riseOverviewBioscience company's Q4 net sales rose 16%, beating analyst expectationsNet income for Q4 declined due to higher operating expensesGross margin improved 160 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL1N3ZS1B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","LU0203347892.USD","BK4567","BK4585","LU0154245756.USD","BK4533","BK4121","BK4183","BK4149","NAGE","CMI","BK4588","LU0203345920.USD"],"gpt_icon":0},{"id":"2617566094","title":"Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566094","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566094?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658381,"startTime":"0","endTime":"0","summary":"NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up momentum.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/03/51050507/niagen-bioscience-doubles-annual-profit-ceo-signals-acquisition-hunt-and-glp-1-style-expansion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4183","NAGE","GLP","BK4144","BK4121"],"gpt_icon":0},{"id":"2617456644","title":"Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617456644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617456644?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658183,"startTime":"0","endTime":"0","summary":"Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million               Niagen Bio reported FY 2025 net sales of USD 129.4 million (+30.0% YoY) and net income of USD 17.4 million (2.0x Yo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4hvxy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"gpt_icon":0},{"id":"2617566458","title":"BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566458","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566458?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658166,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million\n\n\nMar 04 (Reuters) - Niagen Bioscience Inc Q4 net income USD 4.132 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXE0E1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"gpt_icon":0},{"id":"2617569980","title":"Niagen Bioscience Inc Outlook FY Revenue Growth 10-15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569980?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658121,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXE0E1D6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4183","BK4121"],"gpt_icon":0},{"id":"2617661575","title":"Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 Million, 103% Net Income Increase to $17.4 Million or $0.22 Basic EPS in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617661575?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA9TSH7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","NAGE","BK4121"],"gpt_icon":0},{"id":"2614045061","title":"Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC for Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045061","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045061?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:07","pubTimestamp":1772107664,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. said it has sold its ChromaDex Reference Standards business to LGC in an all-cash transaction, effective Feb. 24, 2026. The company said the divestiture is intended to streamline operations and sharpen its focus on NAD+ science, intellectual property, and commercial growth in the longevity market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5PF42V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"gpt_icon":0},{"id":"2614045990","title":"Niagen Bioscience to Streamline and Focus Its Operations With the Sale of Chromadex Reference Standards Business to Lgc in All-Cash Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045990","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045990?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:02","pubTimestamp":1772107320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1LRJV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121","BK4183"],"gpt_icon":0},{"id":"2614004512","title":"Niagen Bioscience Inc - Sells Chromadex Business to Lgc in All-Cash Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2614004512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614004512?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:02","pubTimestamp":1772107320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1LRJV8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"gpt_icon":0},{"id":"2614904080","title":"BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside","url":"https://stock-news.laohu8.com/highlight/detail?id=2614904080","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614904080?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:41","pubTimestamp":1772026883,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide RibosideFeb 25 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE INC - SECURES NEW U.S. PATENT FOR INTRAVENOUS AND INJECTION F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"gpt_icon":0},{"id":"2614080391","title":"Niagen Bioscience Inc - Secures New U.S. Patent for Intravenous and Injection Formulations & Methods of Use for Nicotinamide Riboside","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080391?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:36","pubTimestamp":1772026594,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"gpt_icon":0},{"id":"2614080857","title":"Niagen Bioscience Wins New U.S. Patent for IV and Injectable Nicotinamide Riboside Formulations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080857","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080857?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:32","pubTimestamp":1772026356,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. said it has been granted U.S. Patent No. 12,558,367, covering methods of use of nicotinamide riboside  and derivatives in intravenous and injectable formulations. The company said the patent adds protection for aqueous formulations, multiple administration routes and parameters, select NR salt forms, and combination use with other NAD+ precursors, with expected protection through 2044.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on February 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL2w9L9t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"gpt_icon":0},{"id":"2610265588","title":"Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2610265588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610265588?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:34","pubTimestamp":1770644058,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL38XkG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"gpt_icon":0},{"id":"2610957400","title":"Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610957400","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610957400?lang=en_us&edition=fundamental","pubTime":"2026-02-08 23:10","pubTimestamp":1770563444,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. (NASDAQ: NAGE) previously announced it will report fourth quarter and fiscal 2025 results and host an investor conference call on March 4, 2026, including a general business update following the release of its earnings after market close.\nThe company’s position as a leading NAD+ player, with FDA-recognized Niagen® and defended patents around nicotinamide riboside, highlights a reinforced regulatory moat and product pipeline momentum.\nWe’ll now examine how the upcoming...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/does-niagen-bioscience-nage-still-hold-a-defensible-nad-moat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/does-niagen-bioscience-nage-still-hold-a-defensible-nad-moat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NAGE","NAD"],"gpt_icon":0},{"id":"2609459676","title":"Press Release: Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459676","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459676?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:32","pubTimestamp":1770384720,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. , the global authority on NAD+  with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, March 4, 2026.Webcast link: Niagen Bioscience Fourth Quarter and Fiscal Year 2025 Earnings Conference Call. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.At the heart of its clinically proven produc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4121","NAGE","R","BK4232","BK4585","BK4555","BK4604","BK4099","TM","BK4022","BK4588"],"gpt_icon":0},{"id":"2603247988","title":"BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2603247988","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603247988?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:37","pubTimestamp":1768484247,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru NiagenJan 15 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE INC - PARTNERS WITH TRUEMED TO EXPAND HSA/F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.niagenplus.com","stockEarnings":[{"period":"1week","weight":-0.047},{"period":"1month","weight":-0.187},{"period":"3month","weight":-0.2542},{"period":"6month","weight":-0.4775},{"period":"1year","weight":-0.1145},{"period":"ytd","weight":-0.2343}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.045249},{"month":2,"riseRate":0.5,"avgChangeRate":0.181088},{"month":3,"riseRate":0.3,"avgChangeRate":0.058868},{"month":4,"riseRate":0.555556,"avgChangeRate":0.036039},{"month":5,"riseRate":0.5,"avgChangeRate":0.021036},{"month":6,"riseRate":0.6,"avgChangeRate":0.068253},{"month":7,"riseRate":0.5,"avgChangeRate":-0.007412},{"month":8,"riseRate":0.3,"avgChangeRate":-0.041379},{"month":9,"riseRate":0.3,"avgChangeRate":-0.054309},{"month":10,"riseRate":0.2,"avgChangeRate":-0.056092},{"month":11,"riseRate":0.7,"avgChangeRate":0.200397},{"month":12,"riseRate":0.3,"avgChangeRate":-0.024057}],"exchange":"NASDAQ","name":"Niagen Bioscience","nameEN":"Niagen Bioscience"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Niagen Bioscience(NAGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Niagen Bioscience,NAGE,Niagen Bioscience股票,Niagen Bioscience股票老虎,Niagen Bioscience股票老虎国际,Niagen Bioscience行情,Niagen Bioscience股票行情,Niagen Bioscience股价,Niagen Bioscience股市,Niagen Bioscience股票价格,Niagen Bioscience股票交易,Niagen Bioscience股票购买,Niagen Bioscience股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Niagen Bioscience(NAGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}